19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Community Connect
Lay Counselors, Seeds and Recruits playing key roles in supporting key persons to TB accessing TB test, diagnosis, and treatment during COVID-19
event_note
Loading...
query_builder 10:30 - 11:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Community Connect
mic English
Lay Counselors, Seeds and Recruits playing key roles in supporting key persons to TB accessing TB test, diagnosis, and treatment during COVID-19
COVID-19 restrictions in Cambodia have prevented KHANA and its team from organizing community events for TB awareness and screening, running the outreach mobile digital solutions using GenXpert and X-ray machines to community for TB screening, testing, and diagnosis. So far, KHANA has aimed to increase the community roles in supporting TB affected people to still access to TB testing, diagnosis, and treatment services during the COVID-19 pandemic.  Lay Counselors, Seeds and Recruits who experienced living with TB were contracted to meet one on one with the TB presumptive clients to conduct the pool collection of sputum. After this, the mobile outreach team of GenXpert and X-ray machines were to test and provide the diagnosis on the pool collecting sputum at the health facility. This prevents crowded gatherings, by maintaining the physical distancing, yet increasing the access of TB affected communities to TB testing, diagnosis, and treatment services. From October 1, 2019 to June 30, 2020, within ten rural districts, where the COMMIT project funded by USAID is working, there were 27,917 people screened for TB and out of this, 9,526 identified as TB presumptive clients and 9,241 got TB tests. Amongst those who tested TB, there were 823 cases diagnosed all forms TB and 197 as bacteriologically confirmed TB cases and supported to enroll into treatment.  This result is still less than 50% of the planned target. However, the TB affected people who are demanding TB services were not left behind and were not overlooked during the COVID-19 pandemic.

Sok Chamreun Choub, Executive Director, KHANA
Tuot Sovannary, Research Manager, KHANA
Loading...
Channel 2
OA-33-Overcoming impediments in tobacco control
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-33-Overcoming impediments in tobacco control
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-33-701-24-Monitoring and comparison of the global tobacco and alcohol industry's response to the COVID-19 pandemic This study presents an explorative comparison of tobacco and alcohol industries on their response to the COVID-19 pandemic. It outlines the commercial interests of the corporate social responsibility projects of both industries and observes the similarity in both industries with the growing resistance to its sales and marketing.

Pestheruweliyanaralalage Cooray

11:13 - 11:21: OA-33-702-24-The violation of smoke-free workplace policy in Bali, Indonesia, and the next strategies to improve compliance This was a survey to evaluate smoke-free workplace policy in Bali Province, Indonesia. The results is useful for policy makers to determine the next strategies and actions to improve compliance and achieve 100% smoke-free workplaces.

I Wayan Gede ARTAWAN EKA PUTRA

11:21 - 11:29: OA-33-703-24-Recent smoking cessation in TB patients and risk for TB infection in child household contacts Advocating for smoking cessation among tuberculosis (TB) patients is critical for future global tobacco and TB control. We assessed the impact of recent smoking cessation in pulmonary TB patients on the risk for TB infection in child household contacts in Lima, Peru

Alexander L. Chu

11:29 - 11:37: OA-33-704-24-Effectiveness of behavioural counselling with nicotine gum vs behavioural counselling among TB patients visiting directly observed treatment short-course centres in Delhi, India. The study evidenced an association between tobacco and tuberculosis (TB). Connecting TB and tobacco cessation interventions may produce a positive impact on TB treatment outcomes. The study was done to assess and compare self-reported tobacco quit status, biochemically verified nicotine levels and nicotine dependence among TB patients at different time intervals. 

Sneha Malhotra

11:37 - 11:45: OA-33-706-24-The investment case for tobacco control in five sub-Saharan African countries: a return on investment analysis Few countries have comprehensively implemented the World Health Organization's Framework Convention on Tobacco Control (FCTC) demand-reduction measures. Coordinating with ministries of health, the United Nations Development Programme and the FCTC secretariat, we use a response to intervention-developed model to estimate tobacco-attributable health and economic costs in five sub-Saharan Africa countries. We also explore the return on investment of six demand-reduction measures. 

Garrison Spencer

11:45 - 12:20: Q&A


Loading...
Channel 6
OA-35-New and existing TB drug resistance
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-35-New and existing TB drug resistance
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-35-713-24-Delayed killing of M. tuberculosis in molecular bacterial load assay during early treatment in relapse patients Reliable markers for monitoring tuberculosis (TB) treatment response could accelerate clinical trials and enable personalised treatment.  We evaluated the molecular bacterial load assay (MBLA) that enumerates M. tuberculosis, measuring rRNA as a marker to determine TB-treatment responses. MBLA shows a significant difference between patients with a good long-term outcome, and those with a poor one, early on in treatment.

Nyanda Ntinginya

11:13 - 11:20: OA-35-714-24-Bedaquiline resistance in Mycobacterium tuberculosis predates its clinical use Most clinical bedaquiline resistance is conferred by mutations in the Rv0678 gene, which encodes a negative repressor of the MmpL5 efflux pump. Leveraging global datasets of >1500 lineage 2 and >2000 lineage 4 whole genome sequences, we show that the emergence of Rv0678 variants predates the clinical use of bedaquiline/clofazimine.

Camus Nimmo

11:20 - 11:28: OA-35-715-24-Primary bedaquiline resistance among drug-resistant TB cases in Taiwan Since the emergence of bedaquiline (BDQ) resistance is alarming. It is important to understand the extent of BDQ resistance in drug-resistant tuberculosis (DR-TB) patients and to design a rapid molecular diagnostic algorithm for better management of DR-TB. We identified six novel mutations. 

Sheng-Han Wu

11:28 - 11:36: OA-35-716-24-Mutation in Mycobacterium tuberculosis confer resistance to delamanid in drug-naïve patients Delamanid resistance is associated with mutations in genes of the F420 signalling pathway in Mycobacterium tuberculosis. We searched for such mutations in whole genome sequences of 129 clinical strains collected in countries with high tuberculosis (TB) burdens and their association with in vitro delamanid resistance.

Martina L. Reichmuth

11:36 - 11:44: OA-35-717-24-Heteroresistance as a predictor of treatment outcome among patients with drug-resistant TB in the Philippines We identified heteroresistance as a novel risk factor for unfavourable treatment outcome among patients with multidrug-resistant TB. This suggests that poor outcomes are, in part, due to inadequate treatment of drug-resistant subpopulations below the threshold of detection for phenotypic testing and/or treatment of drug-susceptible populations with second line drugs.

Rebecca Crowder

11:44 - 11:52: OA-35-718-24-­­Genomic context of drug resistance among Mycobacterium tuberculosis in Romania As part of a larger investigation into drug-resistant tuberculosis in the region, we sequenced M. tuberculosis clinical isolate genomes from 200 patients in Romania and performed taxonomic, comparative and predictive bioinformatics analysis. Genomes from Romania samples were compared to genomes from samples previously collected in Moldova, a neighboring, non-EU state.

Brendan Jeffrey

11:52 - 12:00: OA-35-719-24-Minimum inhibitory concentrations variability of Mycobacterium tuberculosis Peruvian strains using the UKMYC6 CRyPTIC plate The Sensititre method uses an UKMYC6 plate, designed by the CRyPTIC consortium, for minimum inhibitory concentration (MIC)-determination of several anti-tuberculosis (TB) drugs. This study evaluated the variability of anti-TB drugs MICs in Peruvian strains.

Zully M Puyén

12:00 - 12:08: OA-35-720-24-Pyrazinamide resistance among rifampicin-resistant TB patients in Yangon, Myanmar: prevalence, clinical characteristics and treatment outcomes Yangon region is reported as the highest multidrug-resistant tuberculosis (MDR-TB) burden area in Myanmar. The study reported the prevalence, clinical characteristics and treatment outcomes in relation to Pyrazinamide (PZA) resistance among rifampicin-resistant TB patients attending TB centres in Yangon in 2019-2020.

Win Ei Phyu

12:08 - 12:19: Q&A


Loading...
Channel 3
SP-41-Preventing human rights abuses in the digitisation of the TB and COVID-19 responses
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-41-Preventing human rights abuses in the digitisation of the TB and COVID-19 responses
*Please scroll down for more information*
The digitalisation of the tuberculosis (TB) response is increasing the amount and kind of data produced and used by public and private health officials. Digital tools for active case finding and adherence, as well as artificial intelligence algorithms, are now being repurposed or broadened for use in the COVID-19 response. Lessons from the HIV and TB responses, for protections of privacy and confidentiality and elimination of stigma and discrimination, must be leveraged for COVID-19. This session will examine the normative, legal and technical aspects of using digital technologies in the TB and COVID-19 responses.  

11:00 - 11:05: Introduction

11:05 - 11:17: Big data in the TB and COVID-19 reponses: a neocolonial and human rights analysisWith the advent of big data comes increased potential for exacerbating disparity through data both directly and indirectly. The production of personal data in high tuberculosis (TB) burden countries, in particular, must be considered in light of their colonial histories. Importantly, interventions intended to eliminate TB at global and national levels are ushering in a new era of data commodification, colonisation, and surveillance in the name of public health. This, in turn, raises critical concerns for the human rights of people affected by TB, many of whom belong to vulnerable or marginalised groups. Importantly, examining the relationship between TB, data surveillance and human rights law does more than illuminate potential pitfalls – it also foreshadows possible solutions.
Kat Albrecht

11:17 - 11:29: Watch out for DAT Trojan horse: DATs v. DOT for TB TreatmentThe proliferation of digital adherence technologies (DATs) in the tuberculosis (TB) response is thought to signal a departure from the longstanding approach of directly observed therapy (DOT). But are the two approaches really any different? This talk will consider whether DATs, rather than representing a true break from DOT, are instead a Trojan horse of sorts. That is, do DATs simply prolong the global community’s reliance on an outdated treatment paradigm, while introducing a whole new set of concerns? This question must be considered in light of the fact that DATs will generate massive amounts of personal data of people affected by TB - some of the most vulnerable people in our communities - for use by government and, in some cases, private health authorities.
Brian Citro

11:29 - 11:41: The risks of digitisation for surveillance and contract tracing for TB and COVID-19Apart from debate on COVID-19, conversations on privacy and data protection have gained momentum over the last few months. Questions have arisen on whether strategies to manage COVID-19 have clawed back on gains made in protection of fundamental rights and freedoms especially the right to privacy. Also, whether such strategies have been well thought out and whether they are in proportion in view of their purpose. There is genuine concern that the surveillance mechanisms that have been adopted by states to deal with the pandemic have gone, or will go, beyond their legal purpose. Surveillance mechanisms have gradually moved from physical surveillance by healthcare professionals to surveillance by security agents and digital surveillance using mobile phone data. Hence, there is need to interrogate what form of digital contact tracing would not pose unnecessary risks to the protection and promotion of fundamental rights and freedoms.
Mugambi Laibuta

11:41 - 11:53: Opportunities and risks for digital technologies in TB community-led monitoringThe reliance on comprehensive, high quality and timely data and information on the barriers faced by people affected by tuberculosis (TB) in accessing essential TB services has given rise to the need for community-led monitoring (CLM) of the TB response and digital CLM solutions.  Intended for collecting, exchanging and making accessible data and information about the TB response as evidence for action, the ultimate aim of CLM is to close the gap in the number of people who fail to receive TB care. Ensuring rights and protections of populations engaged in its pursuit is an ethical and programmatic imperative. This talk will consider the opportunities for digital solutions in CLM, the ethical dilemmas that arise in CLM data management and potential solutions.  
Caoimhe Smyth

11:53 - 12:18: Q&A session

Loading...
Channel 1
OA-32-Reaching the most vulnerable
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-32-Reaching the most vulnerable
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-32-694-24-The positive externalities of migrant-based TB control strategy in a Chinese urban population with internal migration: a transmission- dynamic modelling study We created a transmission-dynamic model of tuberculosis (TB) in the context of large-scale, rural-to-urban migration, using rich demographic, clinical and molecular epidemiology data from Songjiang District, Shanghai. Using this model, we investigated the contribution of different epidemiological mechanisms to TB incidence and assessed the potential impact of new interventions.

Chongguang Yang

11:13 - 11:21: OA-32-695-24-TB whole genome sequencing and MIRU-VNTR analysis in the main foreign-born groups and among Dutch: high transmission in second generation and pre- and post-entry in asylum seekers For targeted tuberculosis (TB) control policies, such as latent TB infection screening in immigrants from high risk-countries, insight in transmission is needed. Whole genome sequencing and MIRU-VNTR phylogenetic analysis maps pre- and post-entry TB transmission within and across foreign-born, second generation and Dutch communities.

Hester Korthals Altes

11:21 - 11:29: OA-32-697-24-High prevalence of smoked illicit substance use in a cohort of patients with drug-susceptible TB in Worcester, South Africa We analysed the prevalence of smoked illicit substance use among a prospective cohort of patients initiating drug-susceptible tuberculosis (TB) therapy in Worcester, South Africa, and evaluated associations of smoked illicit substance use with sociodemographic variables and markers of TB infectiousness.

Bronwyn Myers

11:29 - 11:37: OA-32-698-24-Evaluating access to, and use of, TB and HIV services among urban refugees: developing standardised tools Tuberculosis (TB) and HIV strategic plans often include refugees and asylum seekers but little is known about their access to healthcare, particularly in urban settings. We developed and field-tested knowledge, attitudes and practices tools to assess access to primary care, TB and HIV services among urban refugees and asylum seekers.

Michael Melgar

11:37 - 11:45: OA-32-699-24-Results of the 2019 pilot project on TB screening for residents in shanty towns in South Korea The Korea Centers for Disease Control and Prevention (KCDC) conducted a pilot project for tuberculosis (TB) screening for residents in shanty towns to develop a screening and treatment protocol for TB management of socially, and economically, disadvantaged people. This paper describes the study results.

Eun Hye Shim

11:45 - 11:53: OA-32-700-24-Are humanitarian organisations capable of implementing complex clinical trials? Key insights from a phase II/III multidrug-resistant TB drug trial designed to produce registration standard data (TB-PRACTECAL-NCT02589782) Médecins Sans Frontières (MSF) has implemented TB PRACTECAL, a regulatory-level phase II/III randomised controlled trial, studying six-month oral regimens containing bedaquiline and pretomanid for multidrug-resistant tuberculosis. We aim to share key innovative and successful approaches related to strategic partnering, governance, site selection/support, capacity development and trial monitoring.

Emil Kazounis

11:53 - 12:20: Q&A


Loading...
Channel 4
OA-34-Risk factors, surveillance and control strategies in potential zoonotic TB hotspots
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-34-Risk factors, surveillance and control strategies in potential zoonotic TB hotspots
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-34-707-24-Clustering of Moroccan and Spanish Mycobacterium bovis isolates from slaughtered cattle Bovine tuberculosis (TB) is endemic in Morocco, in addition, zoonotic TB risk is high, but the exact burden is unknown. In this study, we investigated a larger set of Mycobacterium bovis genetic profiles to better define the phylogenetic links between Moroccan isolates and those found worldwide.

Hind Yahyaoui Azami

11:13 - 11:21: OA-34-708-24-Spoligotyping-based direct detection and identification of Mycobacterium tuberculosis complex from cattle samples The public health consequences of Bovine tuberculosis (TB) in India have so far been scarcely investigated and often neglected. India is identified as a high burden country for TB by the World Health Organization and the reports of TB infection in cattle is making the situation even more alarming.  

Kannan Palaniayndi

11:21 - 11:29: OA-34-709-24-Prevalence and risk factors of mycobacterial infections among pastoralists and their cattle in southwestern Nigeria Active case finding of the prevalence and associated risk factors of mycobacterial infections among pastoralist communities - a neglected and high-risk group that are unaware of both their health status and that of their cattle herds - was carried out in Ibarapa area, Oyo State, Nigeria.

Olubukola Adelakun

11:29 - 11:37: OA-34-710-24-Facility-based characteristics are strong predictors of poor TB treatment outcomes in children in Pakistan Few studies have examined predictors of poor tuberculosis (TB) treatment outcomes among children without HIV infection. We assess individual demographic and clinical information as well as facility-based characteristics to identify predictors of unsuccessful paediatric treatment outcomes in children treated for drug-susceptible TB in Pakistan.

Meredith Brooks

11:37 - 11:45: OA-34-711-24-Diagnostic utility of microbiological and histopathological testing in the diagnosis of paediatric TB lymphadenitis in Indian children screened for the SHINE trial The diagnosis of tuberculosis (TB) lymphadenitis in children poses a challenge due to a wide range of differential diagnoses. This is a retrospective study of microbiological (AFB smear, Xpert MTB/RIF, LJ and MGIT cultures) and histopathology testing of peripheral lymphnode samples from children aged<16 years, who were screened for the SHINE trial at Indian sites.

SYED HISSAR

11:45 - 11:53: OA-34-712-24-Thirty-year follow-up of a double-blind randomised, placebo-controlled trial of repeat bacillus Calmette–Guérin vaccination in northern Malawi Forty-seven thousand individuals with bacillus Calmette–Guérin (BCG) vaccine scars were randomised from 1986–89 to receive a second BCG vaccination or placebo. We will present efficacy estimates based on 824 individuals, ascertained with tuberculosis through 2018, including analyses by age, tuberculin status, HIV status and M. tuberculosis lineage.

Paul Fine

11:53 - 12:20: Q&A


Loading...
Channel 5
SP-42-Take home messages for active case finding learned from TB prevalence surveys, TB or not TB?
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-42-Take home messages for active case finding learned from TB prevalence surveys, TB or not TB?
*Please scroll down for more information*
Results from tuberculosis (TB) prevalence surveys using both Xpert MTB/RIF and culture testing raised queries on defining TB due to unexpected discordance in results. As surveys are key to providing insights in a country's TB epidemic it is important there is a good understanding of what we call TB. In this session, key lessons from recent surveys will be discussed from the perspective of the capacity of the diagnostic methods as well as the latest global guidance for the conduct of these surveys. The concluding presentation will provide take-home messages for using these results for active case finding.

11:00 - 11:05: Introduction

11:05 - 11:15: The screening and diagnostic algorithm of national TB prevalence surveys: updated global guidanceResults from recent national TB prevalence surveys have been used to update the guidance from the World Health Organization Global Task Force on TB impact measurement on the screening and diagnostic algorithm of these surveys. This presentation will be informing participants about the recent evidence, a chronology of the discussion and the new guidance.  
Charalampos (Babis) Sismanidis

11:15 - 11:25: GeneXpert and culture for all in the Mozambique national TB prevalence survey, ensuring quality of lab procedures and addressing discordant resultsThis presentation will address the key lessons learned from doing culture and Xpert for all participants in a nationwide survey in Mozambique. For all those with discordant field Gene Xpert and central lab culture results, further laboratory testing was done among which subculture on MGIT. Experiences will be shared on the use of the GeneXpert MTB/RIF in the field setting, the performance of the culture including quality control measures for all samples transported to the National Tuberculosis Reference Laboratory (NTRL) as well as staff management. It will highlight, not only the importance of log tags for quality control of samples sent for culture and the use of controls (positive and negative) in the processing of samples in the NTRL, but also the impact of the survey results for tuberculosis (TB) control on the design of future strategies for TB testing in community settings.
David Macheque

11:25 - 11:35: Strategies to minimise culture in TB prevalence surveys: lessons from targeted culture testing in the TREATS projectTREATS measures the impact of the HPTN071 (PopART) intervention of combined universal HIV and tuberculosis (TB) screening and treatment on the burden of TB at population level. Key to measurement is a TB prevalence survey conducted in 56,000 randomly sampled individuals from the trial communities in Zambia and South Africa. To decide on the best algorithm for the study and contribute to global insights for national surveys, an 'intensive diagnostic phase' was conducted to provide robust evidence on the optimal diagnostics algorithm for use in such TB prevalence surveys, resulting in an innovative algorithm minimising the use of culture. Results will be presented outlining the evidence base behind this algorithm.
Eveline Klinkenberg

11:35 - 11:45: Prevalence surveys: diagnostics unpluggedAs we improve the sensitivity of molecular tests, we in turn increase the positivity rates by detecting cases having very low levels of genomic DNA in sputum. Presumably, one genome of DNA correlates to one cell of Mycobacterium tuberculosis. However, the question arises as to if that cell is actively replicating and causing disease or not. In asymptomatic or questionable cases these results are perplexing and may skew prevalent survey and active case finding results. Further, culturing patients with trace detection results can provide even more confusion when culture practices and methods are flawed. Under these circumstances we often see discordance between molecular and culture results. This conundrum challenges case management. “How does one deal with contradicting results?” This presentation will explain current issues with diagnosis and the reliability of current methods, while providing guidance to clinicians for decision making on case management under these very circumstances.
Kathleen England

11:45 - 11:55: Combining the evidence: what lessons can we learn for active case finding?Tuberculosis (TB) prevalence surveys have provided important insight into the diagnostics of TB and led to a discussion on the definition of TB or not TB. These lessons are also key in the context of active case finding at community level where subclinical disease, or previous TB, might be interfering with the diagnostic test interpretation and the need to decide on what we call TB.
Helen Ayles

11:55 - 12:20: Q&A session

Loading...
Community Connect
Collecting and addressing the barriers to TB care through CLM in EECA
event_note
Loading...
query_builder 11:30 - 12:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Community Connect
mic English
Collecting and addressing the barriers to TB care through CLM in EECA
Community led monitoring via OneImpact App. has been initiated in 4 TB-REP countries to register barriers faced by TB patients, provide real time case by case support and generate data for NTP and local authorizes to inform systemic changes. The adaptation of the OneImpact to country context has been finalized and the tool is currently rolled out in Azerbaijan, Belarus, Kyrgyzstan, Ukraine (Ukraine started earlier with STBP support) and Kazakhstan started the adaptation process of the digital tool in August 2020. Mechanisms for data exchange between the responsible CSO and NTP are established in each country. The monitoring reports on existing barriers based on data in OneImpact are expected to became part of the NTP M&E framework and complement the routinely collected data on services with patients’ feedback on timeliness, quality, accessibility and acceptability. Information from TB patients is collected in 4 TB-REP countries to inform decision making on transformation of the TB care system. Azerbaijan, Belarus, Kyrgyzstan, Tajikistan (the first implementer of OneImpact toll supported by STBP) and Ukraine civil society partners will be invited at the session with a brief information on the process of implementing the CBM using the OneImpact mobile application, the main challenges during the implementation of the CBM using the OneImpact mobile application and lessons learned.

Chairs:
Mari Chokheli 
Cristina Celan

Speakers:
1. Svetlana Nicolaescu, Program Coordinator, PAS Center (Moldova) 
2. Parvana Valiyeva, Executive Director, Saglamliga Khidmat, (Azerbaijan) 
3. Natalya Kryshtafovich, Chair of the Board, Defeat TB Together, (Belarus) 
4. Elena Zhirnova, Project manager, AFEW-Kyrgyzstan, (Kyrgyzstan) 
5. Abdusamad Latifov, Co-founder, Project Coordinator, Stop TB Partnership, Tajikistan, , Tajikistan 
6. Olha Klymenko, Со-founder, Board Chair, Team Leader, Regional Coordinator on Charitable Organization TBpeolpeUkraine, , Ukraine 
7. Vitalina Ustenko, Project Coordinator, TBpeolpeUkraine, , Ukraine
Loading...
Channel 6
OA-38-Diagnostic assays quality and accuracy
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-38-Diagnostic assays quality and accuracy
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-38-735-24-Diagnostic accuracy of the Molbio Truenat TB and RIF-resistance assays in the intended setting of use We evaluated the point-of-care Molbio Truenat molecular diagnostic assays for detection of MTB and RIF resistance in a prospective, multicentre clinical trial in four countries.  We present data on assay performance in microscopy centres/primary health clinics and in reference laboratories, against culture and compared to Xpert MTB/RIF and Ultra.

Adam Penn-Nicholson

12:43 - 12:51: OA-38-736-24-SILVAMP-LAM for the diagnosis of childhood pulmonary TB in Uganda A non-sputum diagnostic for pulmonary tuberculosis (TB) in children is critically needed. Among children with presumptive pulmonary TB in Kampala, Uganda, we evaluated the diagnostic accuracy of the new urine FUJIFILM SILVAMP TB LAM (SILVAMP-LAM) assay in comparison to urine Alere Determine TB LAM Ag (LF-LAM) and sputum smear microscopy.

Devan Jaganath

12:51 - 12:59: OA-38-737-24-Diagnostic accuracy of the Xpert MTB/XDR assay for isoniazid and second line drug resistance detection A preliminary data analysis was conducted from a large-scale, multicentre clinical study of the novel Xpert MTB/XDR assay. It aimed to evaluate diagnostic performance of isoniazid, fluoroquinolone and second line injectable resistance detection against a composite reference standard of phenotypic drug-susceptibility testing and whole genome sequencing.

Adam Penn-Nicholson

12:59 - 13:07: OA-38-738-24-The diagnostic accuracy of Xpert MTB/RIF Ultra for childhood pulmonary TB in Uganda There is limited data on the performance of Xpert MTB/RIF Ultra in children. We prospectively examined the diagnostic accuracy of Xpert Ultra among children with pulmonary tuberculosis (TB) in Kampala, Uganda. We described accuracy overall - and within - subgroups, yield in children with unconfirmed TB and the frequency of trace results.

Peter Wambi

13:07 - 13:15: OA-38-739-24-External quality assurance of the Xpert MTB/RIF Ultra Assay using Mycobacterium tuberculosis isolates inactivated in PrimeStore® Molecular Transport Medium: a safe, simple and local solution Robust external quality assurance (EQA) is essential to ensure accurate results using Xpert Ultra. PrimeStore® Molecular Transport Medium (MTM) inactivates pathogens and stabilises nucleic acids for molecular testing without cold-chain requirements. We tested the idea that Mycobacterium tuberculosis isolates in PrimeStore® MTM could provide a safe, simple and locally-produced method for Xpert Ultra EQA.

Barry Kosloff

13:15 - 13:23: OA-38-740-24-Combination of Xpert MTB/RIF and Determine TB LAM assay improves the diagnosis of extrapulmonary TB in Ethiopia Xpert MTB/RIF and Determine LAM TB assays were complementary for the diagnosis of extrapulmonary tuberculosis and sensitivity of the combination of Xpert MTB/RIF and LAM assays was superior to that of either test alone.

Mulualem Tadesse

13:23 - 13:31: OA-38-741-24-Comparative analytical evaluation of four centralised platforms for the detection of M. tuberculosis complex and detection of resistance to rifampicin and isoniazid Comparative analytical assessment for four fully automated assays for detection of tuberculosis (TB) and multi-drug resistant TB (MDR-TB) - Abbott RealTime MTB and MTB RIF/INH, Hain Lifescience FluoroType® MTBDR BD MAX™ MDR-TB and Roche cobas® MTB and MTB-RIF/INH. Tested against Xpert MTB/RIF and GenoType MTBDRplus as World Health Organization-endorsed comparator tests.

Margaretha de Vos

13:31 - 13:50: Q&A


Loading...
Channel 7
SS4-What can we do to mitigate zoonotic infection risk?
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Special session
mic English
SS4-What can we do to mitigate zoonotic infection risk?
*Please scroll down for more information*
Over just the last 10 years, we have experienced zoonotic disease outbreaks that have had, and are still having, a considerable impact on both animal and human populations. As we are becoming more adept at understanding how to contain and combat disease spread, we recognise that prevention and mitigation starts with animals. Amidst an outbreak it is often human vaccines that seem like the logical area of focus for control yet, ultimately, animal vaccines can be as effective and, in the case of rabies, more effective at slowing the spread. Thus, scientists from the worlds of animal, human and environmental health are beginning to work together more to share knowledge so we can better understand infectious diseases and how they jump from animals to humans. More than 60% of emerging infectious diseases are zoonotic, so keeping animals in good health can be our first line of defence in helping keep outbreaks under control.

12:30 - 12:35: Session introduction


12:35 - 12:45: Zika in Brazil, edidemic spread, consequences for human health and the environment

Jose Eduardo Levi

12:45 - 12:55: SARS-CoV-2 in mink, experiences from the field

Robert Jan Molenaar

12:55 - 13:05: Successful Zika community control programmes in an endemic area

Marianyoly Ortiz

13:05 - 13:15: Community perspective

Timpiyian Leseni

13:15 - 13:45: Live Q&A and moderated discussion


Loading...
Processing. Please wait.
Loading...